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Neuroblastoma and its benign differentiated counterpart, ganglioneuroma, are paediatric neuroblastic tumours arising in the
sympathetic nervous system. Their broad spectrum of clinical virulence is mainly related to heterogeneous biologic background
and tumour differentiation. Neuroblastic tumours synthesize various neuropeptides acting as neuromodulators. Previous
studies suggested that galanin plays a role in sympathetic tissue where it could be involved in differentiation and development.
We investigated the expression and distribution of galanin and its three known receptors (Gal-R1, Gal-R2, Gal-R3) in 19
samples of neuroblastic tumours tissue by immunohistochemistry, in situ hybridization and ﬂuorescent-ligand binding. This study
provides clear evidence for galanin and galanin receptor expression in human neuroblastic tumours. The messengers coding
for galanin, Gal-R1 and -R3 were highly expressed in neuroblastoma and their amount dramatically decreased in
ganglioneuroma. In contrast, Gal-R2 levels remained unchanged. Double labelling studies showed that galanin was mainly co-
expressed with its receptors whatever the differentiation stage. In neuroblastic tumours, galanin might promote cell-survival or
counteract neuronal differentiation through the different signalling pathways mediated by galanin receptors. Finally, our results
suggest that galanin inﬂuences neuroblastoma growth and development as an autocrine/paracrine modulator. These ﬁndings
suggest potential critical implications for galanin in neuroblastic tumours development.
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Neuroblastomas (NB) and neuroblastic tumours (NT) are the
most common extracranial malignant tumours in childhood
(Brodeur et al, 1993). These embryonal malignancies derived
from the sympathoadrenal lineage of the neural crest show a
wide spectrum of differentiation, maturation and organization
of neuroblasts and Schwann cells. Thus, at one end of the spec-
trum there are undifferentiated NT or NB and at the other end
there are the fully differentiated, mature NT or ganglioneuromas
(GN), passing through transitional states or ganglioneuroblasto-
mas (GNB) (Shimada et al, 1999). Most patients with localized
NT can be cured with minimal treatment (Brodeur et al,
1993), whereas, in contrast, children over the age of 1 year with
widely disseminated disease usually have a fatal outcome
(Brodeur et al, 1993; Coze et al, 1997). The spontaneous differ-
entiation and regression of NB reported in some infants is a
salient and a unique feature in human oncology (Brodeur et
al, 1993). This differentiation/regression phenomenon is similar
to programmed cell death as described in the normal develop-
ment of the sympathetic nervous system (Kogner, 1995) and
has been demonstrated to be a valuable target for therapeutic
use (Matthay et al, 1999).
The clinical virulence, differentiation and regression of NT
are reﬂective of the biologic heterogeneity of the tumour.
Genetic abnormalities such as MYCN ampliﬁcation, which are
associated with tumour aggressiveness (Bowman et al, 1997;
Rubie et al, 1997), inhibit the regression of NB (Weiss et al,
1997). The neurotrophin signals, especially those acting through
nerve growth factor (NGF) and its TrkA receptor play an
important role in regulating the regression or differentiation
of NB (Nakagawara and Brodeur, 1997). NB synthesize and
secrete a variety of neuropeptides. The different molecular forms
of neuropeptide Y were associated with NB growth (Bjellerup et
al, 2000), whereas high expression of pancreastatin, vasoactive
intestinal peptide and somatostatin were associated with a
differentiated neuronal phenotype and a favourable prognosis
(Kogner et al, 1995; Albers et al, 2000). The sst2 somatostatin
receptor is considered as a primary target to develop potent
neuropeptides analogues for NB therapy (Borgstrom et al,
1999).
Galanin is a 29 or 30 amino acid peptide with wide-ranging
effects, especially within the neuroendocrine and the central or
peripheral nervous system (Bartfai et al, 1993). Accounting for
the different biological effects, three distinct G-protein-coupled
galanin receptor subtypes termed Gal-R1, Gal-R2 and Gal-R3 have
been cloned in human (Habert-Ortoli et al, 1994; Kolakowski et al,
1998). Experiments in animal models suggest a role for this peptide
within the sympathetic nervous system during its development
(Garcia-Arraras and Torres-Avillan, 1999). No data regarding the
distribution and the role of galanin in the human sympathetic
system is available so far. In a preliminary study, a highly variable
level of galanin expression has been shown in three NB samples
(Tuechler et al, 1998).
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www.bjcancer.comHence, we further investigated the expression and the distribu-
tion of galanin and galanin receptors in NT tissue by using
morphological approaches and addressed the role of this neuropep-
tide in NB differentiation.
MATERIALS AND METHODS
Patients
Nineteen patients were investigated. All the 19 children had newly
diagnosed and previously untreated NT. The diagnosis of NT was
made by histological assessment of a surgically resected tumour
specimen. The tumours were classiﬁed according to the grading
system of Shimada et al. (1999); (1) NB, Schwannian stroma-poor
(UD: undifferentiated, PD: poorly differentiated, D: differentiat-
ing); (2) GNB (nodular or intermixed) and (3) GN, Schwannian
stroma-dominant. The MYCN copy number was determined by
Southern blot analysis. Patients were staged according to the Inter-
national Neuroblastoma Staging System (INSS) (Brodeur et al,
1993). Patients were treated according to protocols described
previously (Coze et al, 1997; Rubie et al, 1997).
In situ hybridization
Preparation of probes Altogether eight oligonucleotide probes
(Eurogentec Bel SA, France) were used in this study for in situ
detection of galanin mRNA (n=2), Gal-R1 mRNA (n=2), Gal-R2
mRNA (n=2), Gal-R3 mRNA (n=2). Sequences were complemen-
tary to the nucleotides 60–107, 139–186 encoding for human
preprogalanin (McKnight et al, 1992), to nucleotides 6–53,
984–1031 of the mRNA encoding the human Gal-R1 (Habert-
Ortoli et al, 1994), to nucleotides 91–138, 1001–1048 of the
mRNA encoding the human Gal-R2 (Kolakowski et al, 1998) and
to nucleotides 41–88, 921–968 of the mRNA encoding the human
Gal-R3 (Kolakowski et al, 1998).
All oligonucleotides were chosen in regions presenting few
homologies with sequences of related mRNAs, and they were
checked against the GenBank database.
For radioactive in situ hybridization, oligonucleotides were
labelled as previously described (Dagerlind et al, 1992) at the 3'-
end using terminal deoxynucleotidyl transferase (TdT) (Amersham,
Amersham, UK), in a cobalt-containing buffer with
35S-dATP
(New England Nuclear, Boston, MA, USA), to a speciﬁc activity
of 1–4610
9 c.p.m. mg
71 and puriﬁed by ethanol precipitation.
For non-radioactive in situ hybridization, 100 pmol of each oligo-
nucleotide probe were labelled at the 3'-end with digoxigenin-11-
dUTP (Boehringer Mannheim, Mannheim, Germany), according
to published protocols (Schmitz et al, 1991).
In situ hybridization procedure Human NB samples, frozen
immediately after sampling, were cut in a cryostat (Microm,
Heidelberg, Germany) and then processed as described earlier
(Broberger et al, 1997), with 0.5 ng of each of the radioactively
labelled galanin or galanin receptor and, when performing double
in situ hybridization, 2 nM of the digoxigenin-galanin probes.
All sections were then dipped into Ilford K5 nuclear emulsion
(Ilford, Mobberly, Cheshire, UK) diluted 1:1 with distilled water,
exposed for three (galanin) and eight (galanin receptor) weeks,
developed and ﬁxed. Some sections were counterstained with cresyl
violet. After mounting in glycerol, the sections were analyzed in a
Zeiss Axiophot 2 microscope equipped with a dark ﬁeld condenser.
Quantiﬁcation The neuronal proﬁles were delineated on coun-
terstained sections and the number of silver grains per cell were
counted automatically on an image analyser (Histo 200, Biocom,
Les Ulis, France) as previously described (Le Moine and Bloch,
1995; Landry et al, 2000). To compare the intensity of galanin
and galanin receptor mRNA labelling according to differentiation
status, grain counting was performed in samples representative of
the two ends of the NT spectrum of differentiation, i.e. NB
(n=7) and GN (n=4). Three sections were counted in each case.
Owing to their nodular or focal heterogeneity, GNB were not taken
in account for grain counting. Results were expressed as a number
of grains per mm
2. Data were presented as mean+standard error;
statistical comparisons were made using the Student t-test.
Immunohistochemistry
The NB samples were immersed in 4% paraformaldehyde for
90 mn and rinsed for at least 24 h in 0.1 M phosphate buffer
(pH 7.4) containing 10% sucrose, 0.02% bacitracin (Sigma, St.
Louis, MO, USA), and 0.01% sodium azide (Merck, Darmstadt,
Germany). The samples were sectioned in a cryostat. The sections
were then incubated with antiserum at 48C for 24 h. Polyclonal
galanin antibodies (1:1000; Peninsula, Belmont, CA, USA) raised
in rabbit were detected with biotin-conjugated goat anti-rabbit
(1:200; Vector Laboratories, Burlingame, CA, USA) and streptavi-
din-ﬂuorescein (1:200; Vector). Monoclonal N-Cam antibodies
(1:1000; Tebu, Le Perray en Yvelines, France) raised in mouse
were detected with rhodamine (TRITC)-conjugated donkey anti-
mouse IgG antibody (1:200; Jackson Immunoresearch, West
Grove, PA, USA). Sections were mounted in an anti-fading solu-
tion and examined in a Zeiss Axiophot 2 ﬂuorescence microscope.
Receptor binding
Binding to galanin receptors was investigated using a ﬂuo-ligand
conjugate, ﬂuo-Gal
TM (Advanced Bioconcept, NEN
TM Life Science
Products, Zaventtem, Belgium), consisting of a ﬂuorophore (ﬂuor-
escein) and the 30 residue human galanin. This peptide was
designed to bind with high afﬁnity to human Galanin-R subtypes
(Mellentin-Michelotti et al, 1999). Cryostat sections were rinsed
twice for 5 mn at room temperature in Neurobasal medium
(Gibco) containing 0.09% glucose, 0.2% Bovine Serum Albumin
(BSA) and 0.02% bacitracin. The sections were preincubated for
10 mn at 48C, then incubated for 60 mn at 48C with 20 nM
ﬂuo-Gal
TM in the same Neurobasal medium solution. The slides
were then rinsed and ﬁxed by incubating in 4% paraformaldehyde
for 20 mn at room temperature. After mounting in para-phenyle-
nediamine (Sigma), the slides were immediately visualised in a
Zeiss Axiophot 2 ﬂuorescence microscope.
Controls
The speciﬁcity of in situ hybridization results was established for
each mRNA species by incubating four control sections with a hybri-
dization cocktail containing an excess (100-fold) of unlabelled probe.
Speciﬁcity of the immunostaining patterns was demonstrated by
preabsorption of the antiserum with the corresponding peptide
(Peninsula).
The speciﬁcity of ﬂuorescent binding was assessed, on serial
sections, by the ability to compete the binding of ﬂuo-Gal
TM using
an excess (100-fold) of unlabelled peptide (Peninsula).
As a control, immunohistochemical studies were also performed
on three paediatric tumours:Wilms’ tumour (n=1), schwannosar-
coma (n=1), and schwannoma (n=1).
RESULTS
Characteristics of NT
Age of the patient, location of the tumour, staging and histological
classiﬁcation are summarized in Table 1. Out of 19 tumours, nine
were NB stroma-poor (one undifferentiated, seven poorly differen-
tiated, one differentiating), six were GNB (two of the intermixed
subtype, four of the nodular one), and four were GN (Schwannian
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British Journal of Cancer (2002) 86(1), 117–122 ã 2002 The Cancer Research Campaignstroma-dominant) (Table 1). The median age at diagnosis was 46
(range, 1 to 124) months. The median follow-up period after diag-
nosis was 24 (range: 2-81) months.
Expression of galanin
Galanin messenger was detected by in situ hybridization in all
tumours investigated (Figure 1A,C and D). Cresyl violet counter-
staining showed silver grains overlying the cytoplasm of neuronal
cell bodies (data not shown). No signiﬁcant signal was seen over
Schwannian stroma cells (Figure 1C,D). Galanin mRNA was found
in the vast majority of neuroblasts whatever the differentiation
stage. A very high number of positive small round-cells was
observed in NB (Figure 1A) whereas only a few labelled large
neuronal cells were detected in GN (Figure 1D), in accordance with
the decrease in cell density. Galanin mRNA-containing cells were
organized in dense clusters in NB (Figure 1A) or in rosette-like
structures in tumours with early neuronal differentiation (Figure
1C), and they appeared sparse within the stroma of GN (Figure
1D).
Grain counting showed that the cellular intensity of the labelling
was lower in GN than in NB (0.22+0.03 grains mm
72 vs
0.42+0.02 grains mm
72, respectively, P50.001) (Figure 2). No
signiﬁcant differences were noticed between metastatic and non-
metastatic NT, or according to the age of the patient or the MYCN
status (data not shown).
Galanin immunoreactivity (-IR) was seen in all tumours investi-
gated. Sections processed for double immunohistochemistry
showed a total overlap of galanin-IR and N-Cam-IR (Figure 3A,B).
As in the in situ hybridization study, the number of galanin-IR
containing cells decreased with cell density (Figure 3A vs 3E). In
GNB, the intensity of the signal was highly variable from one cell
to another with intensely labelled neuroblasts coexisting with weakly
positive ones within the same section (Figure 3C). Moreover, some
ﬁbres were obviously positive in GNB (Figure 3D).
Expression of galanin receptors
Transcripts coding for all three galanin receptors investigated in
this study were found in NT (Figure 4). NB exhibited a homoge-
neous expression of Gal-R1 (Figure 4A), -R2 (Figure 4C) and
-R3 (Figure 4E) mRNAs throughout the whole sample. In GN,
galanin receptor messengers were conﬁned to the scattered neuro-
nal cells, not overlying Schwannian stroma cells (Figure 4B,D and
F). Furthermore, the cellular intensity of galanin-R1 and -R3 label-
ling was intense in NB and decreased in GN (Figure 2: R1:
0.31+0.03 grains mm
72 vs 0.15+0.03 grains mm
72 respectively,
P50.05; R3: 0.21+0.02 grains mm
72 vs 0.13+0.02 grains mm
72
respectively, P50.05). In contrast, galanin-R2 mRNA levels
remained unchanged at the cellular level (Figure 2:
0.26+0.04 grains mm
72 vs 0.31+0.03 grains mm
2, P: NS). No
changes were observed according to the metastatic spread, the
MYCN status or the age of the patient.
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Table 1 Patient characteristics
Tumour Patient’s age INSS Event-free
No (mo)/sex Tumour location stage Histologic type survival (mo)
1 30/F Thorax 4 NB PB, Schwanian Stroma-poor 23
2 67/F Thorax 3 NB PD, Schwanian Stroma-poor 12
3 47/F Retroperitoneum 4 GNB nodular 26
4 42/M Thorax 4 GNB intermixed, Schwanian Stroma-rich 24
5 28/F Retroperitoneum 4 GNB nodular 24
6 47/F Retroperitoneum 4 GNB nodular 5
7 24/M Retroperitoneum 1 GN, Schwanian Stroma-dominant 12
8 18/M Retroperitoneum 4 NB UD, Schwanian Stroma-poor 0
9 1/F Retroperitoneum 3 NB PD, Schwanian Stroma-poor 2
10 23/F Retroperitoneum 3 GNB intermixed, Schwanian Stroma-rich 54
11 4/M Adrenal gland 4 NB PD, Schwanian Stroma-poor 70
12 91/F Thorax 2 GN, Schwanian Stroma-dominant 58
13 47/M Retroperitoneum 4 NB PD, Schwanian Stroma-poor 6
14 46/F Retroperitoneum 4 GNB nodular 12
15 59/M Thorax 4 NB PD, Schwanian Stroma-poor 6
16 1/F Adrenal gland 1 ND PD, Schwanian Stroma-poor 48
17 124/F Thorax 2 GN, Schwanian Stroma-dominant 81
18 84/F Retroperitoneum 3 NB D, Schwanian Stroma-poor 24
19 81/M Thorax 2 GN, Schwanian Stroma-dominant 68
mo=months; INSS=International Neuroblastoma Staging System; NB=neuroblastoma; GN=ganglioneuroma; GNB=ganglioneuro-
blastoma; F=female; M=male; UD=undifferentiated; PD=poorly differentiated; D=differentiating.
Figure 1 Dark-ﬁeld (A,C and D) emulsion dipped autoradiograms of
NT sections after hybridization with
35S-labelled probes complementary
to galanin mRNA. The NB contained a high density of strongly labelled
small round-cells (arrow) (A). In NB, PD, galanin mRNA-containing cells
(arrowhead) were organized in rosette-like structures and no signiﬁcant sig-
nal was seen over Schwannian stroma cells (C). In GN, a few labelled large
neuronal cells (arrow) were detected (D). Brightﬁeld micrograph (B)o fa
section processed for double in situ hybridization visualizing galanin mRNA
using non-radioactive probes and Gal-R1 mRNA, using radioactively-
labelled probes; co-localization between galanin and gal-R1 mRNA (arrow).
Bars indicate 10 mm.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(1), 117–122A high degree of co-localization between galanin and galanin
receptor mRNA was found at the various differentiation stages
investigated as revealed by double in situ hybridization (Figure 1B).
Galanin binding
IncubationofsectionsfromGNwithﬂuorescent-galaninresultedinan
accumulationofbrightspotsoverthecytoplasmofneuronalcellbodies
(Figure 5).They appeared either scattered atthe periphery of theperi-
karya, (Figure 5A,B) or clustered in endosome-like domains (Figure
5B). In a few cases, ﬂuorescent galanin bound to possible neuronal
ﬁbres. In contrast, very weak binding, if any, was detected in NB.
Controls
No radioactive signal was observed after hybridization with an
excess (100-fold) of cold probes. Preabsorption of our antibody
with galanin resulted in an absence of labelling. Incubation of
ﬂuorescent galanin with an excess (100-fold) of unlabelled peptide
totally abolished the signal.
Very weak immunoreactivity, if any, was detected in the three
other paediatric tumour samples (Wilms’ tumour, schwannosarco-
ma, and schwannoma). As an internal control, the NT Schwannian
stroma cells did not show any galanin-IR, any galanin/Gal-R
mRNA labelling or any ﬂuo-Gal
TM binding.
DISCUSSION
This study provides clear evidence for galanin and galanin receptor
expression and regulation in human NT.
Galanin was previously reported to be expressed in small cell
lung cancer (Sethi et al, 1992). Galanin-IR was detected in some
adrenal pheochromocytomas but neither in extra-adrenal paragan-
gliomas nor in medullary carcinomas of the thyroid, in endocrine
tumours arising in the lung, pancreas, or the gastro-intestinal tract
(Sano et al, 1991). Galanin was also shown to be released by
tumoral corticotropes but not by other pituitary adenomas and
appeared to be involved in tumour growth and to be speciﬁcally
regulated (Invitti et al, 1999). Galanin was demonstrated to bind
to its speciﬁc receptors in human pituitary tumours (Hulting et
al, 1993). The present ﬁndings provided a new example of a neural
crest-derived tumour which can be modulated by a strong and
regulated expression of galanin/galanin receptors.
In NT, galanin neurone-speciﬁc expression was demonstrated by
in situ hybridization counterstaining and immunohistochemical co-
localization with N-Cam, a neuronal marker. Our data do not
suggest any relation with the metastatic potential of NT, or with
the MYCN status, perhaps owing to the limited number of patients
investigated in our study. On the other hand, the present study
demonstrates that galanin/galanin receptor expression is related
to the differentiation stage, according to Shimada’s classiﬁcation.
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Figure 3 Immunoﬂuorescence micrographs showing Galanin-IR (A,C–
E) and N-Cam-IR (B). Double immunohistochemistry in NB showed a to-
tal overlap of galanin-IR and N-Cam-IR (arrows) (A,B). Intensely labelled
neuroblasts were seen in GNB, nodular, nodular portion (arrowhead) to-
gether with weakly positive ones (arrow) (C) within the same section. Ga-
lanin-positive ﬁbres (arrow) were detected in GNB, intermixed (D). The
number of galanin-IR containing cells decreased with the neuronal cell den-
sity (A vs E). Bars indicate 50 mm.
Figure 4 Dark-ﬁeld micrographs of emulsion-dipped autoradiograms of
NT tissue after hybridization with
35S-labelled probes complementary to
galanin receptor mRNA. The NB contained a high density of strongly la-
belled small round-cells (arrowheads) (A,C and E). In GN, a weak Gal-
R1 and Gal-R3 mRNA labelling was detected in the few large neuronal cells
(arrows) (B,F) whereas a strong Gal-R2 labelling was observed in neuronal
cells (arrowheads) (D). Bars indicate 10 mm.
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Figure 2 Quantitative evaluation showing the grain densities of labelled
neuronal cells after in situ hybridization for galanin mRNA and galanin re-
ceptor mRNA in NB and GN. Statistical analyses were carried out by using
Student t-test. P value of each counting is indicated. *P50.05. ***P50.001.
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British Journal of Cancer (2002) 86(1), 117–122 ã 2002 The Cancer Research CampaignDuring embryogenesis, galanin was widely expressed in differentiat-
ing neurones of the peripheral nervous system but dramatically
decreased postnatally and was no longer observed in mature prin-
cipal sympathetic neurones of avian models (Barreto-Estrada et al,
1997; Garcia-Arraras and Torres-Avillan, 1999), as well as in rodent
(Xu et al, 1996) and human (Marti et al, 1987; Del Fiacco and
Quartu, 1994) primary sensory neurones. Similarly, in NB, most
undifferentiated neuronal cells displayed robust galanin expression
while its levels were reduced in the well-differentiated GN neuronal
cells.
Furthermore, neuronal cultures of galanin knock-out mice
demonstrated that galanin and its receptors play a critical develop-
mental role and function together with differentiating factors such
as NGF in a molecular cascade to regulate regeneration and neuronal
cell survival (Holmes et al, 2000; O’Meara et al, 2000). In the sympa-
thetic ganglion, injury-induced galanin overexpression was triggered
by deprivation of NGF (Zigmond and Sun, 1997). Similar mechan-
isms promoting tumoral cell survival or counteracting neuronal
differentiation may be also involved in NB where NGF/TrkA interac-
tion induced differentiation of tumour cells (Eggert et al, 2000).
The role of galanin in tumoral cell proliferation or survival may
be exerted in an autocrine/paracrine fashion (Invitti et al, 1999).
This hypothesis is further supported in our study by the co-locali-
zation between galanin and its receptors. In animal models, direct
paracrine effects have already been demonstrated in differentiating
and regenerating neurones (Zigmond and Sun, 1997; Holmes et al,
2000), in the pituitary and in various brain nuclei (Todd et al,
1998). In several human cancers, autocrine or paracrine overactiva-
tion of neuropeptide G-protein-coupled receptors, including those
of galanin, could contribute to neoplasia (Heasley, 2001; Marinis-
sen and Gutkind, 2001). Moreover, some neuropeptide analogues
induce apoptosis in cancer cells where neuropeptide autocrine
and paracrine systems are involved (Heasley, 2001).
GN show speciﬁc features, since they display a relatively high
level expression of Gal-R2 and a clear signal for ﬂuo-Gal binding.
Hence, galanin effects might be exerted through Gal-R2 in differen-
tiated tumoral cells. In contrast, given their high level of
expression, all the three galanin receptors could be considered in
NB. However, the lack of binding suggests the absence of available
receptors at the cell surface. In a previous study, Tuechler et al.
(1998) also suggested that galanin binding was inversely related
to galanin peptide concentration in NB tissue. The exact signiﬁ-
cance of this regulation remains to be elucidated.
The different transduction pathways speciﬁcally associated with
the different galanin receptors may selectively account for distinct
biological activities, including cell-survival and neurite-outgrowth,
and for neuropeptide-stimulated growth of cancer cells (Heasley,
2001). The biological activities of Gal-R1 and -R3 receptors are
mediated by Gi/G0 G-proteins, leading to the inhibition of adenylate
cyclase (Kolakowski et al, 1998). In our study, their associated signal-
ling pathways may have played a role in the poorly differentiated NT
(or NB). In contrast, Gal-R2 biological activity is exerted through
activation of Gq G-protein and phospholipase C and may be involved
in processes prominent during nervous system development (Burazin
et al, 2000). Gal-R2 expression in GN indicates that its associated
signalling pathway might also be involved in NT cell differentiation.
Thus, galanin receptors may be a useful therapeutic target in neuro-
blastoma; in human cancers involving neuropeptide receptors
system, novel molecules have been deﬁned to selectively induce/inhi-
bit one of the G-protein signalling (Heasley, 2001).
The present data suggest that galanin and its receptors are
involved in abnormal differentiation processes of NT. Further
studies are warranted to assign speciﬁc roles to the different galanin
receptors in the modulation of the tumour phenotype and to iden-
tify the clinical implications of the expression of galanin in NT.
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